NCT02860585已完成不适用
Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation
Institut Paoli-Calmettes1 个研究点 分布在 1 个国家目标入组 235 人开始时间: 2013年9月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 235
- 试验地点
- 1
- 主要终点
- Overall Survival according to Immunohistochemical subtypes .
研究概览
简要总结
The objective of this study was to evaluate the outcome of patients affected with different subtypes of metastatic breast cancer following treatment with high-dose chemotherapy and autologous haematopoietic progenitor cell transplantation.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age>18 years
- •Metastatic breast Cancer
- •Treatment with high-dose chemotherapy and autologous haematopoietic progenitor cell transplantation between 2003 and 2012
排除标准
- •Lack of follow-up data
结局指标
主要结局
Overall Survival according to Immunohistochemical subtypes .
时间窗: 8 years
次要结局
- Progression free Survival according to Immunohistochemical subtypes .(8 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study in Second Line Metastatic Colorectal CancerColorectal CancerNCT01183780Eli Lilly and Company1,072
已完成
不适用
Study in Patients With Unresectable And Metastatic Melanoma: The Optimize StudyMelanomaNCT02780089Bristol-Myers Squibb408
已完成
3 期
Study of Cemiplimab in Adults With Cervical CancerSquamous Cell Carcinoma (SCC)Recurrent or Metastatic, Platinum-refractory Cervical CancerNCT03257267Regeneron Pharmaceuticals608
招募中
不适用
Oncologic Outcomes and Toxicities of Salvage Treatment in Patients With Locoregionally Recurrent Breast CancerBreast CancerNCT05933733Samsung Medical Center190
进行中（未招募）
不适用
Evaluation of unfavourable outcome-related factors in patients affected by renal cell cancer in treatment with everolimus and previously treated with a VEGF inhibitor (i.e. sunitinib, sorafenib,pazopanib, or bevacizumab+interferon)EUCTR2014-002508-26-ITIRCCS - Istituto di Ricerche Farmacologiche Mario Negri